1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades neurodegenerativas: desarrollo de terapias

Enfermedades neurodegenerativas: desarrollo de terapias

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Perucho J, Casarejos MJ, Rubio I, Rodriguez-Navarro JA, Gómez A, Ampuero I, Rodal I, Solano RM, Carro E, García de Yébenes J, Mena MA.

    The effects of parkin suppression on the behaviour, amyloid processing, and cell survival in APP mutant transgenic mice

    EXPERIMENTAL NEUROLOGY . 221(1): 54-67. Nº de citas: 15

    [doi:10.1016/j.expneurol.2009.09.029]

  • de Lago E, Gómez-Ruiz M, Moreno-Martet M, Fernández-Ruiz J.

    Cannabinoids, multiple sclerosis and neuroprotection.

    EXPERT REVIEW OF CLINICAL PHARMACOLOGY . 2(6): 645-660.

    [doi:10.1586/ecp.09.42]

  • Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I.

    Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

    Brain . 132(11): 3152-3164. Nº de citas: 260

    [doi:10.1093/brain/awp239]

  • Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J.

    Cannabinoid CB2 Receptor Agonists Protect the Striatum Against Malonate Toxicity: Relevance for Huntington's Disease

    Glia . 57(11): 1154-1167. Nº de citas: 124

    [doi:10.1002/glia.20838]

  • Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J.

    The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages

    BRAIN RESEARCH . 1283: 148-154. Nº de citas: 94

    [doi:10.1016/j.brainres.2009.05.098]

  • Pazos MR, Sagredo O, Fernández-Ruiz J.

    The endocannabinoid system in Huntington's disease

    CURRENT PHARMACEUTICAL DESIGN . 14(23): 2317-2325. Nº de citas: 57

    [doi:10.2174/138161208785740108]

  • Pazos MR, Tolón RM, Benito C, Rodríguez CF, Gorgojo JJ, Nevado M, Alvarez M, Arias F, Almodóvar F, Fernández MT, Lledó JL, González S, Fernández-Ruiz JJ, Romero J.

    Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa

    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY . 56(5): 511-516. Nº de citas: 19

    [doi:10.1369/jhc.2008.950741]

  • Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA.

    Role of CB2 receptors in neuroprotective effects of cannabinoids

    MOLECULAR AND CELLULAR ENDOCRINOLOGY . 286(1-2, 1): 91-96. Nº de citas: 89

    [doi:10.1016/j.mce.2008.01.001]

  • Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J.

    Cannabinoids and neuroprotection in basal ganglia disorders

    MOLECULAR NEUROBIOLOGY . 36(1): 82-91. Nº de citas: 71

    [doi:10.1007/s12035-007-0004-3]

  • García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J.

    Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties

    BRAIN RESEARCH . 1134(1): 162-170. Nº de citas: 206

    [doi:10.1016/j.brainres.2006.11.063]

  • GÓMEZ CAÑAS, MARÍA, FERNÁNDEZ RUIZ, JOSÉ JAVIER.

    Synthesis and pharmacological evaluation of new (E)- and (Z)-3-aryl-4-styryl-1H-pyrazoles as potential cannabinoid ligands

    Arkivoc . 2010: 226-247.

    [doi:10.3998/ark.5550190.0011.a19]